Each month the FormsNet3SM team makes updates to validations, question enabling/disabling and form generation.
The monthly maintenance updates are tentatively scheduled for the 4th Friday of the month.

May 2023 (released May 19, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2450r7 / F2100r4-8 Q16 (F2450) / Q18 (F2100) Validation (Add) “Not Applicable” available as answer option “Not Applicable” will NOT be allowed to be reported for 6M, 1Y, and 2Y reporting periods Consistency with ANC data capture update in April
F4100r8/9 Q180 and 187 (r8) / Q153 and 160 (r9) Validation (Modify) If current treatment path is equal to 2, questions must be answered Disabled for combined follow-up when 2nd event is HCT Burden reduction
F2450r7 / 2011r8 Q67 (F2450) / Q65 (F2100) Answer option reads “PCR (includes quantitative, real time, and fluorescent multiplex)” Option PCR changed to “Single nucleotide polymorphisms (SNPs) (includes quantitative PCR, real-time PCR, sequencing, other)” Updated for more inclusive data capture

April 2023 (released April 21, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2400 r10 Q135 Validation (Add) No option available to report “none” “None” available as answer option Allows “None” as answer without requiring override error code
F2400 r10 Q21 Validation (Modify) If recipient is participating in a clinical trial AND Study Sponsor = Other Sponsor OR Study ID = BMT CTN 1903, then NCT ID must be answered NCT ID required for all clinical trials All clinical trials will report NCT ID.
Exception: RCI BMT studies with no NCT ID – reporting NCT ID will be optional in this case

February 2023 (released February 24, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2600 r5 / r6 Validation (Modify) If HCT = allo unrelated AND product type is BM or PBSC, then GRID must be answered If HCT = allo unrelated AND product type is BM or PBSC OR HCT = allo related and NMDP product, then GRID must be answered Include allo related NMDP product infusions

January 2023 (released January 27, 2023)

Form_Revision Question Type of Change Current New Rationale for Change
F2100 r8 Q136 Validation (Modify) Disabled for the 100 day visit Enabled for both acute and chronic GVHD Allows capture of GVHD that persists across infusions

December 2022 (released December 9, 2022)

Form_Revision Question Type of Change Current New Rationale for Change
F2013 r3 Q3 Validation (Modify) If subsequent transplant or cell therapy, then Q3 is disabled Q3 must be answered for every transplant and cell therapy (regardless if subsequent or first) Provides disease status at latest assessment
F2900 r5 Events & Actions If primary cause of death = COVID-19 OR contributing cause of death contains COVID-19, then a F2149 comes due As of November 2022, F2149 will not come due for TED track (except those enrolled in CTN 2101 study) F2149 is no longer collected for TED track
F2000 r6 Q80 Validation (Modify) No decimal place available when entering dosing weight One decimal place available when entering dosing weight Exact dosing weight necessary to capture data accurately, especially in pediatric patients

November 2022 (released November 18, 2022)

Form_Revision Question Type of Change Current New Rationale for Change
F2450 r7 Events & Actions If Q49 Did the recipient develop COVID-19 since the date of last report = yes, then F2149 comes due for both TED and CRF tracks F2149 will only come due for CRF track and the on demand ability for F2149 on TED track is removed F2149 will only be requested for CRF track

October 2022 (released October 21, 2022)

Form_Revision Question Type of Change Current New Rationale for Change
F2400 r9 Q91 Events & Actions 5 instances allowed for COVID vaccine 8 instances allowed for COVID vaccine Matches the most recent forms
F2400 r9 Q6 Validation (Modify) If country of primary residence = United States, then zip/postal code must be answered If country of primary residence = United States OR US territories, then zip/postal code must be answered All US territories must have zip/postal codes reported
F2400 r9 Q6 Validation (Add) N/A If Q6 country = any United States or US territory, then Q3 Ethnicity must not = N/A Ethnicity must be entered for all states and territories
F2199 r1 Q9 Validation (Modify) If CBC result available is EQUAL TO lymphocytes, then lymphocyte value must be answered If CBC result available CONTAINS lymphocytes, then lymphocyte value must be answered ​If a CBC result has a lymphocyte value, then the value must be reported
F2400 r10 Q20 Validation (Modify) If study sponsor = any (USIDNET, COG, PedAL), then subject ID must be answered If study sponsor = PedAL, then subject ID must be answered. If study sponsor = any other, then subject ID is optional Subject ID only needs to be answered if the study sponsor is PedAL

June 2022 (released June 24, 2022)

Form_Revision Question Type of Change Current New Rationale for Change
F2028 r3 Q78, Q94 Validation (Modify) Currently questions 78 and 94 must be answered, regardless of primary disease If Primary Disease = MDS, ALL, or AML, then Q78 and Q94 will be disabled This information is already captured for these primary diseases, therefore Q78 and Q94 do not need to be answered
F2450 r5 & r6 Q50 Validation (Modify) Q50 MUST be answered Q50 is optional if date of actual contact with the patient is before March 30, 2020 Pre-covid timeframe

May 2022 (released May 20, 2022)

Form_Revision Question Type of Change Current New Rationale for Change
F2400 r9 / F2402 r6 Events & Actions Currently NMDP related donors only get 2006 forms on TED track when repository consent = yes All NMDP related products will receive the 2006 form, regardless of repository consent All NMDP related products should receive the 2006 form
F2100 r7 Q311 Smart Navigation (Modify) ​If Q311 = No, then go to Q315 If Q311 = No, then go to Q312 Date of discharge needs to be reported when procedure was planned to be inpatient.
F2016 r5 Q177 Validation (Add) N/A Q177 must not be equal to Not Applicable Not a real scenario
F2116 r5 Q160/Q187/Q208 Validation (Modify) If Q155 = Yes, then Q160 must be answered If Q158 is = to Known or Unknown, then Q160 must be answered ​Dose should be disabled until the radiation is stopped. If the patient receives therapy across multiple reporting periods, report the total dose all at once after the radiation is stopped

April 2022 (released April 22, 2022)

Form_Revision Question Type of Change Current New Rationale for Change
F2814 r4 Q2 Validation (New) None Q2 Event date: MUST BE NOT EQUAL TO Core: Patient event dates OR Q2 Event date: MUST BE EQUAL TO Core: HSCT Date The CIBMTR is preventing a F2814 being completed for an event already created
F2400 r9 Q23 Validation (Modify) ​If Q18 = yes AND Q49 = yes, then Q23 is optional If Q18 = yes AND Genetically Modified AND Q19 = Other sponsor OR Q21 = BMT CTN 1903 – HIV T Cell, then Q23 must be answered
F2400 r9 / F2402 r6 Events & Actions None If Form Track = CRF AND F2402 Q451 = Transfusion dependent thalassemia, then Forms F2058 and F2158s will generate New disease specific form released in the Spring 2022 release
F2402 r6 Q433 Validation (Modify) If Q427 = yes, then Q433 must be answered If Q428 = yes, then Q433 must be answered Validation was updated to be on the Q428, rather than Q427
F2450 r6 Events & Action If Visit ID = 100 Days and Q48 = Yes, then generate F2553 100 Days If Visit ID = 100 Days and Q48 = Yes, then generate F2553 100 Days AND enroll in study SP16-02 Study enrollment is open
F2100 r6 Events & Action If Visit ID = 100 Days and Q498 = Yes, then generate F2553 100 Days If Visit ID = 100 Days and Q498 = Yes, then generate F2553 100 Days AND enroll in study SP16-02 Study enrollment is open
F4100 r8 Q27 Validation (Modify) ​If Q25 = yes, then Q27 must be answered If Q1 = (Axicabtagene, Brexucabtagene, Ciltacabtegene, Idecabtegene, Lisocabtagene, Tisagenlecleucel), then Q27 must be answered
F2116 r5 Q228 Validation (Modify) ​If Q1 = (AMYL, MGRS, OTH_PCL ) OR Q2 = (AMYL, MGRS), then Q228 must be answered ​​Remove criteria for AMYL, MGRS. These questions should be “must be answered” for all. 
F2116 r5 Q230 Validation (Modify) If Q1 = (AMYL, MGRS) OR Q2 = (AMYL, MGRS), then Q230 must be answered ​​ Remove criteria for AMYL, MGRS. These questions should be “must be answered” for all
F2116 r5 Q232 Validation (Modify) If Q1 = (AMYL, MGRS) OR Q2 = (AMYL, MGRS), then Q232 must be answered ​​Remove criteria for AMYL, MGRS. These questions should be “must be answered” for all

March 2022 (released March 25, 2022)

Form_Revision Question Type of Change Current New Rationale for Change
F4100 r8 Q95 Floating Text (Modify) Q95 floating text currently states: > 100.4 F or > 38 C Q95 floating text modified to ≥ 100.4 F or ≥ 38 C

February 2022 (released Feb 25, 2022)

Form_Revision Question Type of Change Current New Rationale for Change
F2010 r4 Q83 Validation (Modify) Q83 Range for percent disease detected (in blood) must be between 0.001 and 4 Q83 Range for percent disease detected (in blood) must be between 0.001 and 99.999 Range is updated to be consistent with F2111
F2016 r5 Q237 Validation (Modify) If Q236 = Abnormalities identified, then Q237 must be answered disabled question for all ISCN string is not currently collected
F2016 r5 Q243 Validation (Modify) If Q242 = Abnormalities identified, then Q243 must be answered disabled question for all ISCN string is not currently collected
F4100 r8 Q4 Validation (Modify) If the F4000 Q54 = Outpatient and F4100 Visit is 100 days, then F4100 Q4 must be answered If F4000 Q54 = Outpatient, F4100 Visit is 100 days and Current event is Cellular Therapy, then Q4 must be answered Updated so only Cell Therapy events have to answer this question. Previous validation was requiring Q4 to be answered for HCT events that were a part of combined follow-up
F4100 r8 Q27 Validation (Modify) Q27 must be answered If Q25 = Yes, then Q27 must be answered

January 2022 (released Jan 28, 2022)

Form_Revision Question Type of Change Current New Rationale for Change
F2400 r9 Q17 Validation (New) None Q17 “Research Sample Recipient ID” cannot be equal to Q10 “RID IDs cannot be the same
F2400 r9 Q76 Validation (New) None Q76 “Research Sample Donor ID” cannot be equal to Q10 “RID IDs cannot be the same
F2400 r9 / F2402 r6 N/A Events & Actions If form track = CRF and (F2402 Q488 = NEUTD, GST2, HPST2 and Patient is alive), then F2056/2156 generates If form track = CRF and (F2402 Q488 = Chediak-Higashi syndrome, Griscelli syndrome type 2, Hermansky-Pudlak syndrome type 2, Other pigmentary dilution disorder and Patient is alive), then F2056/2156 generates Added ‘Other pigmentary dilution disorder’ to generate the disease specific forms
F2402 r6 Q449 Validation (Modify) If Q2 = IBMFS, then Q449 must be answered (no override allowed) If Q2 = IMBFS, then Q449 must be answered An override can be used on Q449, as not all subtypes (e.g. other, specify) are listed. Centers can leave an override and specify the subtype in the override comment.
F2014 r4 Q152 Validation (Modify) If (Q151 = CR, NR_SD, Prog from HI, Rel from CR) or (Q152 = HI-P, HI-N) or (Q153 = LTB, HTB), then Q154 must be answered If (Q151 = CR, NR_SD, Prog from HI, Rel from CR) or (Q152 contains either HI-P or HI-N) or (Q153 = LTB, HTB), then Q154 must be answered Q152 is a ‘check all that apply’; validation was updated to allow multiple options
F2057 r1 Q208 Validation (Modify) Q208 date must be between the dates reported in Q186 and Q208 Q208 date must be between Q184 and Event date
F2057 r1 Q210 Validation (Modify) Q210 date must be between the dates reported in Q186 and Q208 Q210 date must be between Q184 and Event date
F2100 r7 Q254 Validation (New) None If Q254 contains (BLA, TRANSBRONCH_BIOP, OPEN_VATS, AUTOPSY, OTHR), then Q254 cannot contain No diagnostic tests done If a diagnostic method is selected, then it is not logical to also select ‘No diagnostic tests done’
F2116 r5 Q94 Validation (Modify) If 91 = HEP_RES, NR_SD, PD, then Q94 must be answered If 92 = Known, Unknown, then Q94 must be answered Updated to match the flow of the form and manual
F2116 r5 Q95 Validation (Modify) If 91 = HEP_RES, NR_SD, PD, then Q95 must be answered If Q92 = Known, Unknown, then Q95 must be answered Updated to match the flow of the form and manual
F2116 r5 Q218 Validation (Modify) If Q216 = Known, then Q218 must be answered If Q217 = any M-spike type (excluding ‘No bands present’), then Q218 must be answered
F2116 r5 Q219 Validation (Modify) If Q216 = Known, then Q219 must be answered If Q217 = any M-spike type (excluding ‘No bands present’), then Q219 must be answered
Last modified: May 19, 2023